Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Lenacapavir FDA approval and US Prescribing Information

Thursday 16 February 2023

Following approval by the EMA in the European Union earlier in 2022, lenacapavir (Sunlenca®) received approval by the U.S. Food & Drug Administration (FDA) in December 2022. 

Details from the U.S. Prescribing Information which pertain to specific drug interactions have now been added to the interaction database and are viewable on the website interaction checker alongside those from the European Summary of Product of Characteristics. (Note, the description field which contains product label details is not viewable on the HIV iChart version of the interaction checker.)

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016